Bibliographic Details
| Title: |
Delayed and Concurrent Stereotactic Radiosurgery in Immunotherapy-Naïve Melanoma Brain Metastases. |
| Authors: |
Hadley, Christine E., Matsui, Jennifer K., Blakaj, Dukagjin M., Beyer, Sasha, Grecula, John C., Chakravarti, Arnab, Thomas, Evan, Raval, Raju R., Elder, James B., Wu, Kyle, Kendra, Kari, Giglio, Pierre, Palmer, Joshua D. |
| Source: |
Cancers; Nov2024, Vol. 16 Issue 22, p3733, 14p |
| Subject Terms: |
MELANOMA, RADIOTHERAPY, IMMUNOTHERAPY, TREATMENT effectiveness, METASTASIS, IMMUNE checkpoint inhibitors, DRUG efficacy, TREATMENT delay (Medicine), SURVIVAL analysis (Biometry), BRAIN tumors, OVERALL survival |
| Abstract: |
Simple Summary: Melanoma brain metastases have historically been challenging to treat and have significant effects on the overall survival of these patients. This review article summarizes current treatment modalities including surgery, radiation therapy, and systemic therapies with a focus on immune checkpoint inhibitors. These various treatment options are often used in conjunction to have a greater therapeutic effect on patient outcomes, and this article especially illustrates the role of immunotherapies used alongside stereotactic radiosurgery, a form of radiotherapy. Melanoma remains a formidable challenge in oncology, causing the majority of skin cancer deaths in the United States, with brain metastases contributing substantially to this mortality. This paper reviews the current therapeutic strategies for melanoma brain metastases, with a focus on delayed and concurrent stereotactic radiosurgery (SRS). While surgery and traditional chemotherapy offer limited efficacy, recent advances in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have played a major role in the advancement and improved efficacy of the treatment of cancers, including brain metastases. Recent studies indicate that monotherapy with ICIs may lead to a higher median overall survival compared to historical benchmarks, potentially allowing patients to delay radiosurgery. Other studies have found that combining SRS with ICIs demonstrates promise, with results indicating improved intracranial control. Ongoing clinical trials explore novel combinations of immunotherapies and radiotherapies, aiming to optimize treatment outcomes while minimizing adverse effects. As treatment options expand, future studies will be necessary to understand the interplay between therapies and their optimal sequencing to improve patient outcomes. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
